Onco-proteogenomics identifies urinary S100A9 and GRN as potential combinatorial biomarkers for early diagnosis of hepatocellular carcinoma

BBA Clinical

Volumn 3, Issue , 2015, Pages 205-213

  Huang, Chun Hao ^a,b   Kuo, Chao Jen ^a   Liang, Shih Shin ^a   Chi, Shu Wen ^a   Hsi, Edward ^c   Chen, Chi Chao ^d   Lee, King Teh ^e   Chiou, Shyh Horng ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b INSTITUTE OF BIOLOGICAL CHEMISTRY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d Weill Cornell Medical Center   (United States)

^e KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Granulin; Hepatocellular carcinoma; Protein S100 A9; Proteogenomics; Quantitative proteomics; Urinary biomarkers

Indexed keywords

BIOLOGICAL MARKER; CALGRANULIN B; CEREBROSIDE SULFATASE; GRANULIN; MESSENGER RNA; MICROTUBULE PROTEIN; PEPTIDE; PROTEIN; ROUNDABOUT RECEPTOR; SERINE PROTEINASE INHIBITOR; TRANSCRIPTOME; TREFOIL FACTOR 2; TYROSINE PROTEIN KINASE RECEPTOR UFO; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; GENE AMPLIFICATION; GENE EXPRESSION; GENE MAPPING; GENE ONTOLOGY; GENOMICS; HUMAN; HYDROPHILIC INTERACTION CHROMATOGRAPHY; INFLAMMATION; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; LIVER CELL CARCINOMA; ONCO PROTEOGENOMICS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DATABASE; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; PROTEOMICS; QUANTITATIVE ANALYSIS; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; TANDEM MASS SPECTROMETRY; TRANSCRIPTOMICS; URINALYSIS;

EID: 84924742932     PISSN: 22146474     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbacli.2015.02.004     Document Type: Article

References (54)

1. Villanueva A., Hernandez-Gea V., Llovet J.M. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat. Rev. Gastroenterol. Hepatol. 2013, 10:34-42.
2. Farazi P.A., DePinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 2006, 6:674-687.
3. Sanyal A.J., Yoon S.K., Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist 2010, 15(Suppl. 4):14-22.
4. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., de Oliveira A.C., Santoro A., Raoul J.L., Forner A., Schwartz M., Porta C., Zeuzem S., Bolondi L., Greten T.F., Galle P.R., Seitz J.F., Borbath I., Haussinger D., Giannaris T., Shan M., Moscovici M., Voliotis D., Bruix J. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008, 359:378-390.
5. Huang C.H., Lujambio A., Zuber J., Tschaharganeh D.F., Doran M.G., Evans M.J., Kitzing T., Zhu N., de Stanchina E., Sawyers C.L., Armstrong S.A., Lewis J.S., Sherr C.J., Lowe S.W. CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes Dev. 2014, 28:1800-1814.
6. Goyal L., Muzumdar M.D., Zhu A.X. Targeting the HGF/c-MET pathway in hepatocellular carcinoma. Clin. Cancer Res. 2013, 19:2310-2318.
7. Zhang B., Yang B. Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer. J. Med. Screen. 1999, 6:108-110.
8. Chiou S.H., Wu C.Y. Clinical proteomics: current status, challenges, and future perspectives. Kaohsiung J. Med. Sci. 2011, 27:1-14.
9. Ideker T., Thorsson V., Ranish J.A., Christmas R., Buhler J., Eng J.K., Bumgarner R., Goodlett D.R., Aebersold R., Hood L. Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. Science 2001, 292:929-934.
10. Washburn M.P., Wolters D., Yates J.R. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat. Biotechnol. 2001, 19:242-247.
11. McCormack A.L., Schieltz D.M., Goode B., Yang S., Barnes G., Drubin D., Yates J.R. Direct analysis and identification of proteins in mixtures by LC/MS/MS and database searching at the low-femtomole level. Anal. Chem. 1997, 69:767-776.
12. MacCoss M.J., McDonald W.H., Saraf A., Sadygov R., Clark J.M., Tasto J.J., Gould K.L., Wolters D., Washburn M., Weiss A., Clark J.I., Yates J.R. Shotgun identification of protein modifications from protein complexes and lens tissue. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:7900-7905.
13. Alfaro J.A., Sinha A., Kislinger T., Boutros P.C. Onco-proteogenomics: cancer proteomics joins forces with genomics. Nat. Methods 2014, 11:1107-1113.
14. Laurent-Puig P., Legoix P., Bluteau O., Belghiti J., Franco D., Binot F., Monges G., Thomas G., Bioulac-Sage P., Zucman-Rossi J. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001, 120:1763-1773.
15. Okamoto H., Yasui K., Zhao C., Arii S., Inazawa J. PTK2 and EIF3S3 genes may be amplification targets at 8q23-q24 and are associated with large hepatocellular carcinomas. Hepatology 2003, 38:1242-1249.
16. Sawey E.T., Chanrion M., Cai C., Wu G., Zhang J., Zender L., Zhao A., Busuttil R.W., Yee H., Stein L., French D.M., Finn R.S., Lowe S.W., Powers S. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening. Cancer Cell 2011, 19:347-358.
17. Hoshida Y., Nijman S.M., Kobayashi M., Chan J.A., Brunet J.P., Chiang D.Y., Villanueva A., Newell P., Ikeda K., Hashimoto M., Watanabe G., Gabriel S., Friedman S.L., Kumada H., Llovet J.M., Golub T.R. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 2009, 69:7385-7392.
18. Rivers R.C., Kinsinger C., Boja E.S., Hiltke T., Mesri M., Rodriguez H. Linking cancer genome to proteome: NCI's investment into proteogenomics. Proteomics 2014, 14:2633-2636.
19. Wang X., Slebos R.J., Wang D., Halvey P.J., Tabb D.L., Liebler D.C., Zhang B. Protein identification using customized protein sequence databases derived from RNA-Seq data. J. Proteome Res. 2012, 11:1009-1017.
20. Halvey P.J., Wang X., Wang J., Bhat A.A., Dhawan P., Li M., Zhang B., Liebler D.C., Slebos R.J. Proteogenomic analysis reveals unanticipated adaptations of colorectal tumor cells to deficiencies in DNA mismatch repair. Cancer Res. 2014, 74:387-397.
21. Aquino P.F., Lima D.B., de Saldanha da Gama Fischer J., Melani R.D., Nogueira F.C., Chalub S.R., Soares E.R., Barbosa V.C., Domont G.B., Carvalho P.C. Exploring the proteomic landscape of a gastric cancer biopsy with the shotgun imaging analyzer. J. Proteome Res. 2014, 13:314-320.
22. Wu C.J., Chen Y.W., Tai J.H., Chen S.H. Quantitative phosphoproteomics studies using stable isotope dimethyl labeling coupled with IMAC-HILIC-nanoLC-MS/MS for estrogen-induced transcriptional regulation. J. Proteome Res. 2011, 10:1088-1097.
23. Santos H.M., Kouvonen P., Capelo J.L., Corthals G.L. Isotopic labelling of peptides in tissues enhances mass spectrometric profiling. Rapid Commun. Mass Spectrom. 2012, 26:254-262.
24. Boersema P.J., Aye T.T., van Veen T.A., Heck A.J., Mohammed S. Triplex protein quantification based on stable isotope labeling by peptide dimethylation applied to cell and tissue lysates. Proteomics 2008, 8:4624-4632.
25. Yoshida T. Peptide separation in normal phase liquid chromatography. Anal. Chem. 1997, 69:3038-3043.
26. Yoshida T. Calculation of peptide retention coefficients in normal-phase liquid chromatography. J. Chromatogr. A 1998, 808:105-112.
27. Alpert A.J. Hydrophilic-interaction chromatography for the separation of peptides, nucleic acids and other polar compounds. J. Chromatogr. 1990, 499:177-196.
28. Perkins D.N., Pappin D.J., Creasy D.M., Cottrell J.S. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 1999, 20:3551-3567.
29. Hirosawa M., Hoshida M., Ishikawa M., Toya T. MASCOT: multiple alignment system for protein sequences based on three-way dynamic programming. Comput. Appl. Biosci. 1993, 9:161-167.
30. Mi H., Muruganujan A., Thomas P.D. PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees. Nucleic Acids Res. 2013, 41:D377-D386.
31. Nikolsky Y., Bryant J. Protein networks and pathway analysis. Preface. Methods Mol. Biol. 2009, 563:v-vii.
32. Thomas P.D., Kejariwal A., Guo N., Mi H., Campbell M.J., Muruganujan A., Lazareva-Ulitsky B. Applications for protein sequence-function evolution data: mRNA/protein expression analysis and coding SNP scoring tools. Nucleic Acids Res. 2006, 34:W645-W650.
33. Huang da W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009, 4:44-57.
34. Cerami E., Gao J., Dogrusoz U., Gross B.E., Sumer S.O., Aksoy B.A., Jacobsen A., Byrne C.J., Heuer M.L., Larsson E., Antipin Y., Reva B., Goldberg A.P., Sander C., Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012, 2:401-404.
35. Gao J., Aksoy B.A., Dogrusoz U., Dresdner G., Gross B., Sumer S.O., Sun Y., Jacobsen A., Sinha R., Larsson E., Cerami E., Sander C., Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 2013, 6:l1.
36. Taylor B.S., Schultz N., Hieronymus H., Gopalan A., Xiao Y., Carver B.S., Arora V.K., Kaushik P., Cerami E., Reva B., Antipin Y., Mitsiades N., Landers T., Dolgalev I., Major J.E., Wilson M., Socci N.D., Lash A.E., Heguy A., Eastham J.A., Scher H.I., Reuter V.E., Scardino P.T., Sander C., Sawyers C.L., Gerald W.L. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18:11-22.
37. Roessler S., Jia H.L., Budhu A., Forgues M., Ye Q.H., Lee J.S., Thorgeirsson S.S., Sun Z., Tang Z.Y., Qin L.X., Wang X.W. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res. 2010, 70:10202-10212.
38. Webster J., Oxley D. Protein identification by MALDI-TOF mass spectrometry. Methods Mol. Biol. 2012, 800:227-240.
39. Leonardi G.C., Candido S., Cervello M., Nicolosi D., Raiti F., Travali S., Spandidos D.A., Libra M. The tumor microenvironment in hepatocellular carcinoma (review). Int. J. Oncol. 2012, 40:1733-1747.
40. Budhu A., Wang X.W. The role of cytokines in hepatocellular carcinoma. J. Leukoc. Biol. 2006, 80:1197-1213.
41. Hernandez-Gea V., Toffanin S., Friedman S.L., Llovet J.M. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 2013, 144:512-527.
42. Kurtova A.V., Xiao J., Mo Q., Pazhanisamy S., Krasnow R., Lerner S.P., Chen F., Roh T.T., Lay E., Ho P.L., Chan K.S. Blocking PGE-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature 2015, 517:209-213.
43. Mas V.R., Maluf D.G., Archer K.J., Yanek K., Bornstein K., Fisher R.A. Proteomic analysis of HCV cirrhosis and HCV-induced HCC: identifying biomarkers for monitoring HCV-cirrhotic patients awaiting liver transplantation. Transplantation 2009, 87:143-152.
44. Avci M.E., Konu O., Yagci T. Quantification of SLIT-ROBO transcripts in hepatocellular carcinoma reveals two groups of genes with coordinate expression. BMC Cancer 2008, 8:392.
45. Lee H.J., Jeng Y.M., Chen Y.L., Chung L., Yuan R.H. Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma. Carcinogenesis 2014, 35:769-775.
46. Wu R., Duan L., Ye L., Wang H., Yang X., Zhang Y., Chen X., Weng Y., Luo J., Tang M., Shi Q., He T., Zhou L. S100A9 promotes the proliferation and invasion of HepG2 hepatocellular carcinoma cells via the activation of the MAPK signaling pathway. Int. J. Oncol. 2013, 42:1001-1010.
47. Ho J.C., Ip Y.C., Cheung S.T., Lee Y.T., Chan K.F., Wong S.Y., Fan S.T. Granulin-epithelin precursor as a therapeutic target for hepatocellular carcinoma. Hepatology 2008, 47:1524-1532.
48. Cheung S.T., Wong S.Y., Leung K.L., Chen X., So S., Ng I.O., Fan S.T. Granulin-epithelin precursor overexpression promotes growth and invasion of hepatocellular carcinoma. Clin. Cancer Res. 2004, 10:7629-7636.
49. Fujimoto A., Totoki Y., Abe T., Boroevich K.A., Hosoda F., Nguyen H.H., Aoki M., Hosono N., Kubo M., Miya F., Arai Y., Takahashi H., Shirakihara T., Nagasaki M., Shibuya T., Nakano K., Watanabe-Makino K., Tanaka H., Nakamura H., Kusuda J., Ojima H., Shimada K., Okusaka T., Ueno M., Shigekawa Y., Kawakami Y., Arihiro K., Ohdan H., Gotoh K., Ishikawa O., Ariizumi S., Yamamoto M., Yamada T., Chayama K., Kosuge T., Yamaue H., Kamatani N., Miyano S., Nakagama H., Nakamura Y., Tsunoda T., Shibata T., Nakagawa H. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat. Genet. 2012, 44:760-764.
50. Zimmermann U., Feneux D., Mathey G., Gayral F., Franco D., Bedossa P. Chromosomal aberrations in hepatocellular carcinomas: relationship with pathological features. Hepatology 1997, 26:1492-1498.
51. Yano H., Nanashima A., Hidaka S., Haseba M., Tanaka K., Yamaguchi H., Nakagoe T., Tagawa Y., Nagayasu T. Numerical aberrations of chromosome 17 and the p53 locus in small hepatocellular carcinomas. Anticancer Res. 2004, 24:111-115.
52. Jia H.L., Ye Q.H., Qin L.X., Budhu A., Forgues M., Chen Y., Liu Y.K., Sun H.C., Wang L., Lu H.Z., Shen F., Tang Z.Y., Wang X.W. Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin. Cancer Res. 2007, 13:1133-1139.
53. Uchino K., Tateishi R., Shiina S., Kanda M., Masuzaki R., Kondo Y., Goto T., Omata M., Yoshida H., Koike K. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer 2011, 117:4475-4483.
54. Ko B.S., Chang T.C., Hsu C., Chen Y.C., Shen T.L., Chen S.C., Wang J., Wu K.K., Jan Y.J., Liou J.Y. Overexpression of 14-3-3 epsilon predicts tumour metastasis and poor survival in hepatocellular carcinoma. Histopathology 2011, 58:705-711.